Top

Published in:

01-07-2017 | Original Scientific Report

The Role of ¹⁸F-fluorodeoxyglucose Positron Emission Tomography-Computed Tomography for Predicting Pathologic Response After Induction Therapy for Thymic Epithelial Tumors

Authors: Koichi Fukumoto, Takayuki Fukui, Toshiki Okasaka, Koji Kawaguchi, Shota Nakamura, Shuhei Hakiri, Naoki Ozeki, Tomoshi Sugiyama, Katsuhiko Kato, Kohei Yokoi

Published in: World Journal of Surgery | Issue 7/2017

Abstract

Background

We investigated the role of ¹⁸F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in predicting the effect of induction therapy in patients with thymic epithelial tumors.

Methods

Fourteen patients with thymic epithelial tumors who underwent PET-CT before and after induction therapy were retrospectively analyzed. The relationship between the change in the maximum standardized uptake value (SUV_max) in PET-CT, the response evaluation criteria in solid tumors and the pathologic response (Ef0, no necrosis of tumor cells; Ef1, some necrosis of tumor cells with more than one-third of viable tumor cells; Ef2, less than one-third of tumor cells were viable; and Ef3, no tumor cells were viable) was analyzed.

Results

The study cohort consisted of 5 males and 9 females. Nine of the patients had thymoma, and 5 had thymic carcinoma. The induction therapy included chemotherapy in 9 cases, chemoradiation therapy in 4 cases and radiation therapy in 1 case. Among the 8 patients with a pathologic response of Ef0/1, 5 were clinically evaluated as having stable disease (SD), while 3 were found to have had a partial response (PR). The SUV_max was elevated in 2 cases, unchanged in 1 and decreased in 5. On the other hand, 3 of the 6 patients with a pathologic response of Ef2, 3 were classified as having SD, while the other 3 had a PR. The SUV_max decreased in all of the patients.

Conclusions

In comparison with CT, PET-CT seems to be useful for predicting the pathologic response to induction therapy in patients with thymic epithelial tumors.

Masuda M, Kuwano H, Okumura M et al (2015) Thoracic and cardiovascular surgery in Japan during 2013: annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 63:670–701CrossRefPubMedPubMedCentral

Fischer B, Lassen U, Mortensen J et al (2009) Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 361:32–39CrossRefPubMed

Liu J, Dong M, Sun X et al (2016) Prognostic value of ¹⁸F-FDG PET/CT in surgical non-small cell lung cancer: a meta-analysis. PLoS ONE 11:e0146195CrossRefPubMedPubMedCentral

Groheux D, Sanna A, Majdoub M et al (2015) Baseline tumor ¹⁸F-FDG uptake and modifications after 2 cycles of neoadjuvant chemotherapy are prognostic of outcome in ER +/HER2 − breast cancer. J Nucl Med 56:824–831CrossRefPubMed

Kittaka H, Takahashi H, Ohigashi H et al (2013) Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy in patients with resectable T3 pancreatic cancer. World J Surg 37:169–178. doi:10.1007/s00268-012-1775-x CrossRefPubMed

Maffione AM, Marzola MC, Capirci C et al (2015) Value of ¹⁸F-FDG PET for predicting response to neoadjuvant therapy in rectal cancer: systematic review and meta-analysis. AJR Am Roentgenol 204:1261–1268CrossRef

Cerfolio RJ, Bryant AS, Winokur TS et al (2004) Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 78:1903–1909CrossRefPubMed

Ozeki N, Kawaguchi K, Fukui T et al (2015) Which variables should be considered in patients with stage II and III non-small cell lung cancer after neoadjuvant therapy? Nagoya J Med Sci 77:475–480PubMedPubMedCentral

Kukar M, Alnaji RM, Jabi F et al (2015) Role of repeat ¹⁸F-fluorodeoxyglucose positron emission tomography examination in predicting pathologic response following neoadjuvant chemoradiotherapy for esophageal adenocarcinoma. JAMA Surg 150:555–562CrossRefPubMed

10.

Cheng L, Tunairu N, Collins DJ et al (2015) Response evaluation in mesothelioma: beyond RECIST. Lung Cancer 90:433–441CrossRefPubMed

11.

Kaira K, Murakami H, Miura S et al (2011) ¹⁸F-FDG uptake on PET helps predict outcome and response after treatment in unresectable thymic epithelial tumors. Ann Nucl Med 25:247–253CrossRefPubMed

12.

Thomas A, Mena E, Kurdziel K et al (2013) ¹⁸F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors. Clin Cancer Res 19:1487–1493CrossRefPubMedPubMedCentral

13.

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed

14.

Masaoka A, Monden Y, Nakahara K et al (1981) Follow-up study of thymomas with special reference to their clinical stages. Cancer 48:2485–2492CrossRefPubMed

15.

Fukumoto K, Taniguchi T, Ishikawa Y et al (2012) The utility of [¹⁸F]-fluorodeoxyglucose positron emission tomography-computed tomography in thymic epithelial tumours. Eur J Cardiothorac Surg 42:e152–e156CrossRefPubMed

16.

Japan Lung Cancer Society (2003) General rule for clinical and pathological record of lung cancer, 7th edn. Kanehara, Tokyo, pp 175–177

17.

Yokoi K, Matsuguma H, Nakahara R et al (2007) Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone. J Thorac Oncol 2:73–78CrossRefPubMed

18.

Treglia G, Sadeghi R, Giovanella L et al (2014) Is ¹⁸F-FDG PET useful in predicting the WHO grade of malignancy in thymic epithelial tumors? A meta-analysis. Lung Cancer 86:5–13CrossRefPubMed

19.

Terzi A, Bertolaccini L, Rizzardi G et al (2011) Usefulness of ¹⁸F FDG PET/CT in the pre-treatment evaluation of thymic epithelial neoplasms. Lung Cancer 74:239–243CrossRefPubMed

20.

Shiono S, Abiko M, Okazaki T et al (2011) Positron emission tomography for predicting recurrence in stage I lung adenocarcinoma: standardized uptake value corrected by mean liver standardized uptake value. Eur J Cardiothorac Surg 40:1165–1169PubMed

Title: The Role of 18F-fluorodeoxyglucose Positron Emission Tomography-Computed Tomography for Predicting Pathologic Response After Induction Therapy for Thymic Epithelial Tumors
Authors: Koichi Fukumoto
Takayuki Fukui
Toshiki Okasaka
Koji Kawaguchi
Shota Nakamura
Shuhei Hakiri
Naoki Ozeki
Tomoshi Sugiyama
Katsuhiko Kato
Kohei Yokoi
Publication date: 01-07-2017
Publisher: Springer International Publishing
Published in: World Journal of Surgery / Issue 7/2017
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-017-3938-2

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The Role of ¹⁸F-fluorodeoxyglucose Positron Emission Tomography-Computed Tomography for Predicting Pathologic Response After Induction Therapy for Thymic Epithelial Tumors

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2017

Delayed Laparoscopic Cholecystectomy for Acute Calculous Cholecystitis: Is it Time for a Change?

Surgical Treatment of Gastroesophageal Reflux Disease

ISS Symposium From Heartburn to Barrett’s Esophagus, and Beyond

Surgical Treatment of High-Grade Dysplasia and Early Esophageal Cancer

Does Beta-Blockade Reduce the Risk of Depression in Patients with Isolated Severe Extracranial Injuries?

The Effect of Three-Dimensional Preoperative Simulation on Liver Surgery